<DOC>
	<DOC>NCT01884948</DOC>
	<brief_summary>To study the efficacy and safety of intravenous Omegaven™ (vs. Placebo) in reducing postoperative morbidity and mortality after major liver resection.</brief_summary>
	<brief_title>Effects of Omega-3 Fatty Acids on Outcome After Major Liver Resection</brief_title>
	<detailed_description>With two single doses of Omegaven (pre- and postoperatively) we aim to reduce postoperative complications measured by the CCI (Comprehensive Complication Index) and the Clavien Dindo classification of surgical complications. The study will include adults (more than 18 years) patients requiring liver resection of at least 1 segment or multiple wedge resections (≥3).</detailed_description>
	<criteria>Inclusion criteria: Requiring liver resection of at least 1 segment or multiple wedge resections (=3) &gt; 18 years of age No coagulopathy (INR &lt; 1.2, platelets &gt;150'000 x10E3/µl) Understands local language Exclusion criteria: Liver resections &lt;1 segment Wedge resections (&lt;3) Liver cirrhosis Coagulopathy (INR &gt; 1.2, platelets &lt; 150'000 x10E3/µl) Hypertriglyceridemia (&gt; 5.0 mmol/l) Hypersensitivity or allergy to Omegaven™ or any fish oil or lipid emulsions Known allergy to egg protein Pregnancy Nursing women Renal failure(estimated GFR &lt; 30 ml/min/1.73m2) Medication impairing platelets aggregation Cannot understand local language</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>at least 1 segment</keyword>
	<keyword>multiple wedge resections (≥3)</keyword>
</DOC>